The Paid Promotion Weekly Wrap Up October 31, 2021
Welcome to the third weekly wrap up for Paid Promotions. This will be a free weekly series that will catch you up on recent paid promotions ran during the week, news and stock performance from prior paid promotions. I plan to write more about trends, the different players involved, and deeper analysis of the targeted companies from the paid stock promotions. Any comments or feedback is appreciated.
This week’s Paid Promotion Weekly Wrapup is sponsored by unhedged.com, which is a finance platform that makes it easy to track news, filings, events, and reports with real time information and data. It is fast becoming my favorite website to build the newsletter and follow my investments. Make sure you subscribe to their newsletters “Highlights of the Week”, “Weekly Market Recap”, and “Markets: The Week Ahead”.
A very quiet week on the paid promotion front. Other than a late Friday $10,000 promotion on $BTCY by FierceAnalyst there was not a whole lot to report on new paid promotions for the week. It was a great week for $SYTA up 59% for the week and hit a high of $9.68 up 200%+ on 147M+ shares on October 27, 2021 before fading back lower. $IFBD closed up 15%, and $MYMD was up 9.5%. The losers for the week were $FDCT down 27%, $ALF 20.6%, and $KWEMF down 6.3%. $BTCY continues to trade over $4.00 building a pretty good base and I am watching all dips getting bought up. I am curious how it will trade if the paid promotions finally are stopped.
Prior Paid Promotions Making News:
$SYTA announced a new funding agreement with Lind Global Partners II for $6M.
$ALF disclosed they put senior management on paid administrative leave and a leadership transition. The company was a target of Bleeker Street in a short report that has done very well so far.
$MDGS announced they will form a new joint venture to trade NFT assets and plan to invest up to $5M.
$KWEMF announced the development of a new system to counter “Loitering Munitions”.
$KTTA announced they successfully treated the first patients in the UK with Ketamine infusion therapy.
My paid promotion email box has been very quiet all weekend and I am hoping to see a few previews teased for next week.